Why do so many promising immunotherapies fail to reach their potential? Adrian Hayday argues that transformative clinical advances depend on protecting specialized ‘squares of discovery’ in which deep understanding and unexpected insights emerge, while building stronger pathways to biotechnology, pharmaceutical development and patient care.
原文链接
分享
引用
